Fig. 5From: A novel tumor mutational burden estimation model as a predictive and prognostic biomarker in NSCLC patientsGene expression differences between the estimated high TMB and low TMB groups. a–f TMB-associated pathways, such as inflammatory response, TNF-α signaling via NFκB, interferon α response, IL6-JAK-STAT3 signaling, interferon γ response, and allograft rejection. NES, normalized enrichment score; FDR, false discovery rateBack to article page